REFERENCES
1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22.
2. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015;136:2187-95.
3. Konturek A, Barczyński M, Stopa M, Nowak W. Trends in prevalence of thyroid cancer over three decades: a retrospective cohort study of 17,526 surgical patients. World J Surg 2016;40:538-44.
4. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016;12:646-53.
5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
6. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-83.
7. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-8.
8. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh) 1993;128:230-4.
9. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998;338:712-8.
10. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005;294:71-80.
11. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007;92:2190-6.
12. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799-809.
13. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52.
14. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31:4046-53.
15. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 2013;31:468-74.
16. Izkhakov E, Keinan-Boker L, Barchana M, et al. Long-term all-cause mortality and its association with cardiovascular risk factors in thyroid cancer survivors: an Israeli population-based study. BMC Cancer 2020;20:892.
17. Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000;85:159-64.
18. Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 2006;16:381-6.
19. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8.
20. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995;80:2222-6.
21. Taillard V, Sardinoux M, Oudot C, et al. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy. Clin Endocrinol (Oxf) 2011;75:709-14.
22. Gazdag A, Nagy EV, Erdei A, et al. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer. J Endocrinol Invest 2015;38:133-42.
23. Abdulrahman RM, Delgado V, Hoftijzer HC, et al. Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid 2011;21:471-6.
24. Abonowara A, Quraishi A, Sapp JL, et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin Invest Med 2012;35:E152-6.
25. Horne MK 3rd, Singh KK, Rosenfeld KG, et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab 2004;89:4469-73.
26. Pajamäki N, Metso S, Hakala T, et al. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2018;88:303-10.
27. Suh B, Shin DW, Park Y, et al. Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea. Eur J Endocrinol 2019;180:11-20.
28. Izkhakov E, Meyerovitch J, Barchana M, Shacham Y, Stern N, Keinan-Boker L. Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors. Endocr Connect 2019;8:398-406.
29. Zoltek M, Andersson TM, Hedman C, Ihre-Lundgren C, Nordenvall C. Cardiovascular Incidence in 6900 Patients with Differentiated Thyroid Cancer: a Swedish Nationwide Study. World J Surg 2020;44:436-41.
31. Blackburn BE, Ganz PA, Rowe K, et al. Aging-related disease risks among young thyroid cancer survivors. Cancer Epidemiol Biomarkers Prev 2017;26:1695-704.
32. Toulis KA, Viola D, Gkoutos G, Keerthy D, Boelaert K, Nirantharakumar K. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease. Clin Endocrinol (Oxf) 2019;91:323-30.
33. Park J, Blackburn BE, Ganz PA, et al. Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah cancer survivors study. J Clin Endocrinol Metab 2018;103:2468-77.
34. Lin CY, Lin CL, Lo YC, Kao CH. Association between radioiodine treatment for thyroid cancer and risk of stroke. Head Neck 2017;39:2311-8.
35. Kim KJ, Song JE, Kim JY, et al. Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study. Ann Transl Med 2020;8:1235.
36. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 2008;18:141-4.
37. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf) 2005;62:487-91.
38. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007;92:491-6.
39. Izkhakov E, Vaisman N, Barnes S, Barchana M, Stern N, Keinan-Boker L. Body composition, resting energy expenditure, and metabolic changes in women diagnosed with differentiated thyroid carcinoma. Thyroid 2019;29:1044-51.
40. Wolf M, Weigert A, Kreymann G. Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy. Eur J Endocrinol 1996;134:168-73.
41. Ito M, Miyauchi A, Kang S, et al. Effect of the presence of remnant thyroid tissue on the serum thyroid hormone balance in thyroidectomized patients. Eur J Endocrinol 2015;173:333-40.
42. Lovejoy JC, Smith SR, Bray GA, et al. A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men. J Clin Endocrinol Metab 1997;82:765-70.
43. Lebon V, Dufour S, Petersen KF, et al. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle. J Clin Invest 2001;108:733-7.
